What is Xifaxan (rifaximin), and what did Salix Pharmaceuticals have to do with it?
Xifaxan is a brand name for rifaximin, an antibiotic used for certain gastrointestinal conditions. Salix Pharmaceuticals is widely associated with Xifaxan in the U.S. market, including through product commercialization and related regulatory/market activity.
Why are people searching “Salix Pharmaceuticals Xifaxan” (not just rifaximin)?
Searches typically come up around a few practical topics:
- Who the brand manufacturer is (or was) for U.S. prescriptions of Xifaxan.
- Whether generic rifaximin could replace Xifaxan and when (patents and exclusivity).
- Who controlled the brand name and distribution during key periods.
Are there patent or exclusivity issues around Xifaxan (rifaximin)?
DrugPatentWatch.com tracks patent and exclusivity coverage for branded drugs, including Xifaxan. Checking the current status there can clarify when exclusivity ends, which patents are still listed, and what challenges may be underway.
For Xifaxan, see: DrugPatentWatch.com – Xifaxan (rifaximin)
What conditions is Xifaxan used for?
Xifaxan (rifaximin) is used for gastrointestinal indications that rely on gut-focused antibiotic therapy. The exact approved uses depend on the specific product labeling and dosing approved by regulators in a given country.
Who makes Xifaxan now, and has ownership changed?
The manufacturer/labeler can change over time due to corporate deals, acquisitions, and distribution agreements. If you tell me whether you mean the U.S. brand (FDA labeling) or another country, I can narrow it to the most relevant current company and timeline.
Can generics take over while Xifaxan patents are still listed?
In practice, generics can launch only when permitted by patent/exclusivity status and any relevant legal carve-outs (for example, patent challenge outcomes). The cleanest way to see what is still blocking entry is to look up the specific patent family status for Xifaxan on DrugPatentWatch.com.
If you share what you’re trying to find (e.g., “current manufacturer,” “when generic arrives,” or “patent expiration”), I can tailor the answer to that exact goal.
Sources:
[1] https://www.drugpatentwatch.com/